Jasper Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell-driven diseases. The company's lead product candidate is briquilimab, a novel targeted aglycosylated monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. This mechanism disrupts critical survival signals, depleting mast cells via apoptosis and addressing the underlying source of inflammatory responses. Jasper's primary clinical focus is on Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma. Historically, the company explored hematopoietic stem cell transplant conditioning regimens, but those programs have been discontinued to focus exclusively on mast cell-driven diseases.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
On June 1, 2026, Jasper announced that its Board of Directors initiated a comprehensive review of strategic alternatives to maximize shareholder value. The board is evaluating options including a sale of assets, licensing of assets, collaborations, a sale of the company, a business combination, merger, or an orderly wind-down of operations.
Expected impact: A potential transaction or corporate restructuring to address the company's severe capital constraints.
Advancing the clinical development of briquilimab, a novel monoclonal antibody targeting c-Kit (CD117), for mast cell-driven diseases. The company refiled an updated Phase 2b protocol with the FDA for its planned Phase 2b study in Chronic Spontaneous Urticaria (CSU) following positive clinical data from its BEACON and open-label extension studies.
Expected impact: Establishment of registrational clinical data and proof-of-concept for briquilimab in CSU.